In this sense, our group has recently developed a therapeutic cancer vaccine candidate called PKPD-L1Vac, which contains as an antigen the extracellular domain of human PD-L1 fused to a 47 amino-terminal, part of the LpdA gene of N. meningitides, which is produced in E. coli. Previous non-clinical studies have demonstrated that the immunization of mice with PKPD-1Vac promoted not only a highly specific immune response but also a potent anti-tumoral effect in both syngeneic BALB/c and C57BL/6 mouse models [10]. Here, CD274 is linked to cancer.